Actinium (NYSE: $ATNM) Announces Pricing of Public Offering of Common Stock

Actinium (NYSE: $ATNM) Announces Pricing of Public Offering of Common Stock

NEW YORK - September 29, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $1.25. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about October 4, 2016, subject to customary closing conditions.

The gross proceeds to Actinium from this offering is expected to be $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Actinium. Actinium currently intends to use the net proceeds from the sale of securities for general corporate purposes, including capital expenditures, the advancement of its drug candidates in clinical trials, such as Iomab™-B and Actimab™- A, preclinical trials, and to meet working capital needs.

H.C. Wainwright & Co. is acting as sole book-running manager for the offering. JonesTrading Institutional Services LLC is acting as co-manager for the offering. ROTH Capital is acting as a financial advisor for the offering.

The offering is being conducted pursuant to a shelf registration statement that was previously filed with, and declared effective by, the U.S. Securities and Exchange Commission ("SEC"). Prospective investors should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Actinium has filed with the SEC for more complete information about Actinium and the offering. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available free of charge on the website of the SEC at www.sec.gov. Electronic copies of the preliminary prospectus supplement and accompanying prospectus and, when available, the prospectus supplement and the accompanying prospectus may also be obtained from the offices of H.C. Wainwright & Co., LLC by emailing placements@hcwco.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Read this release in full at http://www.investorideas.com/CO/ATNM/news/2016/09291CommonStock.asp

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.

Reign Sapphire (OTCQB: $RGNP) Launches the Inaugural Reign #Sapphire Jewelry Collections Look Book and Style Guide

Reign Sapphire (OTCQB: $RGNP) Launches the Inaugural Reign #Sapphire Jewelry Collections Look Book and Style Guide

BEVERLY HILLS, CA - September 29, 2016 (Investorideas.com Newswire) Reign Sapphire Corporation, (OTCQB: RGNP) ("Reign" or the "Company"), which produces and markets Australian Sapphire Jewelry, today announced the launch of its Inaugural Reign Sapphires Jewelry Collections Look Book and Style Guide, presenting Reign's lifestyle campaign and jewelry collections recently launched on www.reignsapphires.com.

The Reign Sapphires Jewelry Collections Look Book and Style Guide features images of Reign Sapphires's three distinct inaugural jewelry collections, Reign Opulence, Reign Signature and Reign Classics, featuring rings, bracelets and necklaces, predominantly comprised of 1.5mm to 4.5mm diamond and princess cut sapphire melees.

"We are thrilled to present our Look Book and Style Guide to the world of fashion and jewelry," said Joseph Segelman, CEO.

The Inaugural Reign Sapphires Jewelry Collections Look Book and Style Guide compiles everything that Reign's Inaugural Sapphire Jewelry Collections have to offer in one volume of high-quality images.

Reign Sapphire's all-natural, conflict free, ethically processed gemstones are mined in Australia from verified sources. They are guaranteed natural gems of certified origin, manufactured under guaranteed ethical and sustainable processes, with the only enhancement being heat treatment of color.

Reign Sapphire Corporation purchases rough sapphires in bulk directly from commercial miners in Australia and closely controls and manages each step along the supply chain, from sorting, polishing and cutting to faceting, jewelry design and manufacturing and sales of finished Reign sapphire jewelry.

Read this release in full at: http://www.investorideas.com/news/2016/luxury-brand/09292JewelryRGNP.asp

About Reign Sapphire Corporation

Based in Beverly Hills, California, Reign Sapphire Corporation is a fully reporting, DTC eligible public company, established as a "miners-gate to retail" model for rough sapphires to finished jewelry; a color gemstone brand; and a jewelry brand featuring Australian sapphires. Reign Sapphire Corporation is not an exploration or mining company.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Reign Sapphire Corporation ("Reign" or the "Company"). Forward-looking statements are based on the expectations, estimates, or projections of the Company's management as of the date of this press release. Although Reign's management believes these expectations, estimates, or projections to be reasonable as of the date of this presentation, forward-looking statements are inherently subject to significant business risks, economic and competitive uncertainties, or other contingencies, which could cause the Company's actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Reign's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" sections in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2015, which is available for viewing on the SEC's EDGAR website. These forward-looking statements speak only as of the date of this press release and, except as required by law, Reign specifically disclaims any obligation to update these forward-looking statements, even if new information becomes available in the future.

Corporate Contact

Joseph Segelman, CEO
9465 Wilshire Boulevard
Beverly Hills, CA 90212
(213) 457-3772

Investor Relations Contact

CorProminence LLC
Scott Arnold, Managing Director
377 Oak Street
Garden City, NY 11530
(516) 222 2560

SOURCE: Reign Sapphire Corporation

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp 

Disclosure: Reign Sapphire Corporation (OTCQB: RGNP) is a paid client effective September 28, 2016 for one month of news publication and social media: two thousand five hundred.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

CTO of Gopher Protocol (OTCQB: $GOPH) Shares Results of Recent Real-Time Tracking Test of the Guardian Patch Location Technology in San Diego

CTO of Gopher Protocol (OTCQB: $GOPH) Shares Results of Recent Real-Time Tracking Test of the Guardian Patch Location Technology in San Diego

Company’s Unique Tracking Technology Positions for Global Pet Wearable Market

San Diego, California, Point Roberts WA, - September 28, 2016 - Investorideas.com, a global news source covering tech stocks interviews Dr. Danny Rittman, CTO of Gopher Protocol Inc. (OTCQB:GOPH) following the recent successful live demonstration and testing of the Guardian Patch held in San Diego on September 14^th, 2016. 

The Guardian Patch is a stick-on patch location technology that can track a phone, a pet collar, a child’s backpack and anything you want to personally track.

Dr. Rittman shares the recent testing results and also discusses the company’s plan to enter the global pet wearable market with the pending release of their Guardian Sphere tracking device.

Interview

Q: Investorideas.com

Danny, congratulations on the recent successful first live test and demonstration of the Guardian Patch. Can you tell us what object(s) you tracked and for how long?  

A: Danny Rittman, CTO of Gopher Protocol Inc.

We tracked a car that I drove, travelling along typical roads and highways. The LIVE DEMO took about 1 hour. During the DEMO I stopped at a few locations to demonstrate the accuracy of the tracking system, in real time, if needed.

Q: Investorideas.com

This first live demo was in a 50 mile radius in San Diego. Can you tell us the challenges you faced in this demo and also what surprised you, if anything, as you went through the testing?

A: Danny Rittman, CTO of Gopher Protocol Inc.

The main challenge was to keep the real-time aspect. Although the final Patch will transmit its location every certain amount of time (in some applications even just twice a day, each application will determine the time interval), this DEMO focused on real time response. We achieved amazing results by keeping continuous, smooth tracking of my location at all times with intervals of about 10 seconds. One of my associates said: “Danny, you bring satellite from the sky to the ground, so exciting.”

Q: Investorideas.com

Now that you have done a successful tracking in a 50 mile radius area, what will the next testing parameters include and can you estimate when and where that will take place?

A: Danny Rittman, CTO of Gopher Protocol Inc.

The next DEMO will be to cover a greater distance. Then once we complete this, we will probably demonstrate the Guardian Sphere which is a local tracking device, targeted for applications like tracking pets, kids…or any other object that is not supposed to move.

Q: Investorideas.com

The Guardian Patch works with or without GPS, so in your next series of testing will you show how it tracks in areas without GPS capabilities? And on that note, can you briefly explain how that works? How you can locate a person or object where there is no access to GPS?

A: Danny Rittman, CTO of Gopher Protocol Inc.

The current system already has a partial GeoLocation mechanism. In future DEMOs, we will demonstrate live tracking without GPS by simply blocking the “eye-in-the-sky” access. This will be done by entering a closed location like a tunnel or similar.

Q: Investorideas.com

The Company is looking at all potential applications for the unique tracking technology and just announced the development of the Guardian Sphere tracking device, primarily created for the pet market.  Can you tell us what differentiates it from the Patch and how it works?

A: Danny Rittman, CTO of Gopher Protocol Inc.

The Guardian Sphere is a local tracking device that can be used for pets, objects and even children, team members at tradeshows, hospital patients, or any other object that is not supposed to move (like hospital equipment, and similar). It is targeted to track in a radius of 5-10 miles. With existence of similar Guardian Sphere devices in the area, this range can be easily extended. This tracking device includes similar technology aspects as the Patch and is targeted for local operation.

Q: Investorideas.com

The global pet wearable market is expected to reach USD 2.36 billion by 2022 according to some analysts. Do you see this as one of your biggest market opportunities? 

A: Danny Rittman, CTO of Gopher Protocol Inc.

Given this estimated market share, I think that there is a great opportunity for the Guardian Sphere since it is the leader in its domain. There is no similar device currently in the market that offers such large range with the possibilities of extension.

Q: Investorideas.com

So for consumers and investors following the Company, what is the next phase of development to expect prior to the official consumer launch of your products?

 

A: Danny Rittman, CTO of Gopher Protocol Inc.

Due to demand, we are now focused on rapid manufacturing of the Guardian Sphere, targeting Q1 or Q2 of 2017 to be available for sale. As the Sphere itself “keeps evolving” as an independent product, I cannot guarantee the timing, as adding features extends the development. For example, just lately we are thinking of an additional light button for the Sphere. But in essence, the Sphere and introduction to the market ASAP is our first priority.  In parallel, we continue to develop the Guardian Patch, targeted for later in 2017.

Tracking map area of recent live demo:

About Guardian Patch http://www.guardianpatch.com/

The Guardian Patch (the "Patch"), potentially arriving in consumer markets in 2017, is a unique location technology that works with or without GPS. The Patch is a "stick-on" device that provides its users with the capability to protect and track objects, a loved-one or even a pet, through a mobile application. Download the Patch app, register your patch, and track anything that you own on your mobile device or on our designated website. Register the Patches of your family members and friends to receive alerts in the event of an emergency. Peel the Patch off and the Patch acts as a beacon, sending out a signal and notifying anyone who has registered the user's Patch.

About Gopher Protocol Inc.   http://gopherprotocol.com

Gopher Protocol Inc. (OTCQB: GOPH) ("Gopher" and the "Company") (http://gopherprotocol.com) is a development-stage company developing a real-time, heuristic-based mobile technology. Upon development, the technology will consist of a smart microchip, mobile application software and supporting software that will run on a server. The system contemplates the creation of a global network. Gopher believes this will be the first system that is developed using a human, heuristic-based analysis engine. Since the core of the system will be its advanced microchip technology that will be capable of being installed in any mobile device worldwide, Gopher expects that this will result in an internal, private network between all mobile devices utilizing the microchip by providing mobile technology for computing power enhancement, advanced mobile database management/sharing and other additional mobile features.

Corporate Site: http://gopherprotocol.com

Press page/ press kit - http://gopherprotocol.com/?page_id=228

Consumer and product website for Guardian Patch: http://www.guardianpatch.com/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GOPH is a PR , social media and publishing client and compensates Investorideas.com (  effective April 4, 2016 - three thousand five hundred per month )More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

About Investorideas.com - Global news source covering leading sectors including technology.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Contact Investorideas.com

800 665 0411

NXT-ID, Inc. (NASDAQ: $NXTD) Receives Letter from NASDAQ Confirming it has Regained Listing Compliance

NXT-ID, Inc. (NASDAQ: $NXTD) Receives Letter from NASDAQ Confirming it has Regained Listing Compliance

WorldVentures to Showcase New Smart Card at NXT-ID Booth.

MELBOURNE, Florida - September 28, 2016 (Investorideas.com Newswire) NXT-ID, Inc. (NASDAQ:NXTD) (NXTDW) ("NXT-ID" or the "Company"), a company focused on the growing mobile commerce announces that it has received a letter from NASDAQ dated September 27th confirming that it has regained compliance with the minimum bid price listing requirement. The Company has satisfied the terms of the NASDAQ Listing Qualifications Panel by complying with the minimum bid price requirement of $1.00 per share under NASDAQ Listing Requirement 5550(a)(2). Accordingly, NASDAQ has advised that the matter is now closed.

Read this release in full at http://www.investorideas.com/CO/NXT/news/2016/09281Regained.asp

About NXT- ID Inc. - Mobile Security for a Mobile World

NXT-ID, Inc.'s innovative MobileBio® solution mitigates consumer risks associated with mobile computing, M-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio suite of biometric solutions that secure consumers' mobile platforms. With extensive experience in Biometric Identity Verification, Security and Privacy, Encryption and Data Protection, Payments, Miniaturization and Sensor technologies, the Company partners with industry leading companies to provide solutions for modern payment and IoT applications.

http://nxt-id.com/, http://wocketwallet.com/.

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

NXT- ID Inc Contact:

Corporate info: info@nxt-id.com

Media:

D. Van Zant
+1-800-665-0411
press@nxt-id.com

Visit this company: nxt-id.com; 3d-id.net; wocketwallet.com/

More info on NXTD at Investorideas.com Visit: http://www.investorideas.com/CO/NXT/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: As of October 1, 2015 NXT-Id renewed for one year –five thousand per month and fifteen thousand 144 restricted shares for PR, media and marketing. http://www.investorideas.com/About/Disclaimer.asp and http://www.investorideas.com/About/News/Clientspecifics.asp

Actinium (NYSE: $ATNM) Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60

Actinium (NYSE: $ATNM) Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60

Webinar to be held at 9:00 AM ET to highlight Actimab-A Phase 2 clinical trial and protocol revisions agreed to by the FDA

Protocol revisions agreed to by the FDA include the use of peripheral blast burden as an inclusion criteria, the mandated use of Hydroxyurea in patients with high peripheral blast burden and the elimination of low dose cytarabine

Trial will enroll 53 patients in a multicenter, open-label study designed to evaluate patient complete response rates and overall survival

NEW YORK - September 27, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has initiated a Phase 2 clinical trial of Actimab-A in patients newly diagnosed with Acute Myeloid Leukemia (AML) who are over the age of 60. Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program consists of the CD33 targeting monoclonal antibody, HuM195, and the alpha-emitting radioisotope, actinium-225.

"We are excited to have initiated the Phase 2 trial of Actimab-A for elderly patients who are newly diagnosed with AML and ineligible for 7+3 treatment. These older patients face a poor prognosis and have limited viable treatment options" said Sandesh Seth, Actinium's Executive Chairman. "We are encouraged by the safety and efficacy signals we have seen thus far and look forward to the execution of this trial with an eye toward interim and top-line results which are both expected in 2017."

This Phase 2 clinical trial is a multicenter, open-label study that will enroll 53 patients. Patients will receive 2.0 µCi/kg/fractionated dose of Actimab-A via two injections given at day 1 and day 7. The Phase 2 trial is designed to evaluate complete response rates at up to day 42 after Actimab-A administration, where complete response is defined as complete remission (CR) or complete remission with incomplete platelet recovery (CRp). A formal interim analysis is expected to occur in mid-2017 with topline results expected in the second half of 2017. The Phase 2 trial will include peripheral blast burden as an inclusion criteria and in patients with high peripheral blast (PB) burden, the use of Hydroxyurea will be mandated with the goal of bringing PB burden below a key threshold number that the Company has identified from two previously complete Phase 1 clinical trials totaling 38 patients. In addition, the use of granulocyte colony-stimulating factors (GCSF) will be mandated. Low dose cytarabine has been eliminated from the protocol and the Phase 2 clinical trial will evaluate Actimab-A as a monotherapy. The secondary endpoint of the Phase 2 trial will be overall survival.

Dr. Joseph Jurcic, Principal Investigator of the Actimab-A Phase 2 trial and Director of Hematologic Malignancies; Professor of Medicine at Columbia University Medical Center said, "Actimab-A has been studied in two clinical trials thus far in patients with AML ranging in age from 18-87 who had a wide array of genetic risk factors that were at various stages of disease progression. Actimab-A has shown a promising safety and efficacy profile thus far that we believe differentiates Actimab-A from other CD33 targeting drug candidate, which is an exciting space in AML. Our PB burden hypothesis indicates that of all factors related to AML including age, stage of disease and genetic factors, peripheral blast burden showed to be the most relevant. With PB burden serving as an inclusion criteria in this Phase 2 trial and the use of Hydroxyurea being mandated in patients with PB burden above a key threshold we look forward to conducting this clinical trial in this older patient population that has a great unmet medical need."

The Company will host a webinar Tuesday, September 27, 2016 at 9:00 AM ET to discuss the Phase 2 clinical trial. Details for the webinar are as follows:

Date: Tuesday, September 27, 2016 
Time: 9:00 AM ET 
Webinar Link: https://onecast.thinkpragmatic.com/ses/awQiM-9OD7Iysoul6ZD6BQ~~ 
Speakers: Joseph Jurcic, M.D., Director of Hematologic Malignancies; Professor of Medicine at Columbia University Medical Center
Actimab-A Principal Investigator 
Sandesh Seth, Executive Chairman, Actinium Pharmaceuticals 
Dragan Cicic, M.D., Chief Medical Officer, Actinium Pharmaceuticals

Read this release in full at http://www.investorideas.com/CO/ATNM/news/2016/09271Actimab-A.asp

About Actimab-A

Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program, is being prepared for a Phase 2 clinical trial for patients newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. HuM195 is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and HuM195 were initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a second-generation therapy from the Company’s HuM195-Alpha program, which has now been studied in almost 90 patients in four clinical trials.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.

Actinium Pharmaceuticals (NYSE: $ATNM) to Sponsor and Participate in Be The Match® Walk+Run to Raise Awareness for Bone Marrow Transplant

Actinium Pharmaceuticals (NYSE: $ATNM) to Sponsor and Participate in Be The Match® Walk+Run to Raise Awareness for Bone Marrow Transplant

NEW YORK - September 26, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has sponsored and will participate in the upcoming Be The Match® Walk+Run being held on Saturday, October 1, 2016, at Firefighter's Field on Roosevelt Island, New York, New York. The goal of the Walk+Run is to raise awareness for bone marrow transplant (BMT), raise funds to help transplant patients, support marrow transplant research and add more potential marrow donors to the Be The Match Registry®.

Employees of Actinium Pharmaceuticals, together with their family and friends, will be participating in the Be The Match® Walk+Run to raise awareness and funds. To support Team Actinium and Be The Match® , please visit Actinium's team page here: Click here to view the team page for Team Actinium

"Actinium is focused on developing products which may improve the lives of patients with leukemia, lymphoma or one of the many other life-threatening diseases that could benefit from a bone marrow transplant," stated David Gould, M.D., Actinium's Senior Vice President of Corporate Development and Corporate Affairs. "Be The Match provides incredible support to these patients and we are honored to have the ability to sponsor such a worthwhile event and we are excited to participate in the Walk+Run on October first."

About Be The Match®

For people with life-threatening blood cancers—like leukemia and lymphoma—or other diseases, a cure exists. Be The Match connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant. People can contribute to the cure as a member of the Be The Match Registry, financial contributor or volunteer. Be The Match provides patients and their families one-on-one support, education, and guidance before, during and after transplant.

Be The Match is operated by the National Marrow Donor Program® (NMDP), a nonprofit organization that matches patients with donors, educates health care professionals and conducts research so more lives can be saved. To learn more about the cure, visit BeTheMatch.org or call 1 (800) MARROW-2

Read this release in full at http://www.investorideas.com/CO/ATNM/news/2016/09261BoneMarrowTransplant.asp

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Be the Match Foundation®
Melissa Neill
Strategic Public Relations Specialist
763-406-8762

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.